Abstract 184P
Background
Pancreatic cancer remains a highly lethal malignancy with limited treatment options for metastatic and recurrent cases. Nanoliposomal-irinotecan and fluorouracil with leucovorin (NFF) has emerged as the standard treatment following gemcitabine-based regimens. However, the relationship between treatment outcomes and neutropenia in pancreatic cancer has not been thoroughly investigated.
Methods
In this retrospective study, we analyzed data from 161 patients with pancreatic cancer treated with NFF. Neutropenia was assessed based on the Common Terminology Criteria for Adverse Events (CTCAE) cutoffs: Cutoff A (CTCAE Grade 0 versus Grade 1–4), Cutoff B (Grade 0–1 versus Grade 2–4), and Cutoff C (Grade 0–2 versus Grade 3–4). The primary endpoint was overall survival (OS), while secondary endpoints included response rate (RR), progression-free survival (PFS), and relative dose intensity (RDI).
Results
Among the 161 patients, 93/8/22/30/8 had Grade 0/1/2/3/4 neutropenia, respectively. Baseline patient characteristics, including white blood cell (WBC) count, neutrophil count, lymphocyte count, C-reactive protein (CRP) levels, and FU RDI, exhibited significant differences (p<0.05) between two groups separated by Cutoff A and Cutoff B. Additionally, WBC count, neutrophil count, and FU RDI differed significantly (p<0.05) at Cutoff C. Fisher’s exact test revealed significant differences (p<0.05) in RR at Cutoff C, with the odds ratio of Cutoff C being the greatest, followed by Cutoff B and A. Regarding OS, there were significant differences at Cutoff A (hazard ratio (HR), 0.65; 95% CI, 0.44–0.94; p<0.05) and Cutoff B (HR, 0.63; 95% CI, 0.43–0.92; p<0.05), but not at Cutoff C (HR, 0.73; 95% CI, 0.47–1.14; p=0.16). Furthermore, there were significant differences in PFS at Cutoff A and B (p<0.05). Cox regression analysis indicated that neutropenia was significantly associated with OS at Cutoff A and B (adjusted p<0.05).
Conclusions
NFF-induced neutropenia exhibits significant potential as both a predictive factor for treatment response and a prognostic factor for OS in patients with pancreatic cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
321P - Epidemiology and survival analysis of epithelial ovarian cancer: Results from comprehensive care center in north India
Presenter: Amit Badola
Session: Poster Display
Resources:
Abstract
322P - Evaluation of chemotherapy response score as a prognostic factor in advanced epithelial ovarian cancer: A prospective single centre study
Presenter: Upasana Palo
Session: Poster Display
Resources:
Abstract
323P - Platelet-to-lymphocyte ratio, neutrophil-to-lymphocyte ratio, and lymphocyte-to-monocyte ratio as prognostic biomarkers in ovarian cancer among the Asian population: A meta-analysis
Presenter: Wikania Wira Wiguna I Gede
Session: Poster Display
Resources:
Abstract
324P - All-<italic>trans</italic> retinoic acid sensitizes ovarian cancer to niraparib by inhibiting ALDH1A1 activity
Presenter: Bingjie Mei
Session: Poster Display
Resources:
Abstract
325TiP - A phase III randomized controlled trial in primary stage three and four ovarian cancer after interval cytoreductive surgery (FOCUS/KOV-HIPEC-04)
Presenter: Myong Cheol Lim
Session: Poster Display
Resources:
Abstract
327TiP - A single arm phase II study of single agent pemetrexed in platinum resistant/refractory epithelial ovarian or primary peritoneal cancer
Presenter: Swasthik Parampalli
Session: Poster Display
Resources:
Abstract
337P - Demographic patterns and survival outcomes of patients with T and NK-cell lymphoma at the National Cancer Centre Singapore
Presenter: Mohamed Haniffa Bin Hasan Mohamed
Session: Poster Display
Resources:
Abstract
338P - Multicenter real-world study of advanced-stage non-nasal type NK/T cell lymphoma (NKTCL): Clinical features, treatment and prognosis
Presenter: Yuce Wei
Session: Poster Display
Resources:
Abstract
339P - A comparison of survival of patients with relapsed or refractory diffuse large B cell lymphoma undergoing allogeneic stem cell transplantation or receiving CAR-T therapy
Presenter: Kenta Hayashino
Session: Poster Display
Resources:
Abstract
340P - The role of CT scans and laboratory tests for surveillance in patients with diffuse large B cell lymphoma who achieved complete remission after first-line chemotherapy
Presenter: YU Yagi
Session: Poster Display
Resources:
Abstract